Arbutus Biopharma (ABUS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.42
- Estimate
- -$0.03
- Surprise
- +1613.6%
- Revenue (period 2026-09-30)
- $299,000
- Score today
- 6.0/10
Revenue source: xbrl.
How the report landed
Arbutus Biopharma (ABUS) beat the -$0.03 estimate with adjusted EPS of $0.42 — a large 1613.6% upside surprise.
Coverage in the report window
- Arbutus Biopharma Reports Third Quarter 2026 Financial Results and Corporate Update — fiscal.ai, 2026-11-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates ABUS Hold at 6.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +1613.6% surprise compares with a +976.1% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Counterparty: Moderna
- Negative momentum
- Below 200-MA, MA slope -1.3%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.82
- Price target
- $4.56
- Stop
- $3.55
- Upside to target
- +19.4%
- Reward-to-risk
- 2.0:1
Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.
ABUS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $585.5M
- P/E (fwd)
- -23.1
- P/E (ttm)
- 3.4
- 52-week range
- $3.50–$5.45
- Off 52-week high
- 29.9%
- RSI (14)
- 37
- Volume vs avg
- 0.94×
- Score today
- 6.0/10